Apomorphine still leads, but ropinirole expands emetic options

CURRENT BRIEF VERSION: A growing body of evidence is sharpening the choice between two familiar emetics in dogs: apomorphine and ropinirole. Ropinirole ophthalmic solution, marketed in the U.S. as Clevor, was approved by the FDA in June 2020 as a prescription-only option for inducing vomiting in dogs, giving clinics a non-injectable alternative to apomorphine and the only FDA-approved veterinary emetic for this use. In the approval field study, 95% of treated dogs vomited within 30 minutes, and 86% did so after the first dose. Since then, newer comparative studies have added nuance: a 2025 blinded crossover trial in 24 healthy dogs found ropinirole and IV apomorphine had similar overall efficacy and adverse-effect rates, while two clinical-setting studies reported that ropinirole was effective, but generally slower and, in some settings, less successful on the first dose than apomorphine. In a 2025 emergency-room trial across two specialty hospitals, dogs that received ropinirole were also more likely to have prolonged vomiting and need rescue antiemetics after recent toxin or foreign-body ingestion. (fda.gov)

Why it matters: For veterinary professionals, the choice is becoming less about whether ropinirole works and more about where it fits best in workflow and case selection. Apomorphine still appears to have an edge when rapid decontamination is the priority, especially in emergency presentations involving recent toxin or foreign material ingestion. But ropinirole offers a practical ophthalmic option that avoids IV access and has an FDA-approved canine label, which may be attractive in general practice or selected ER cases. Current toxicology guidance still emphasizes that emesis itself is not benign, and that patient history, timing, contraindications, and the nature of the ingested material should drive the decision before either drug is used; dogs with caustic or volatile ingestions, aspiration risk, neurologic concerns, or other contraindications should not be routine candidates for induced emesis. (pubmed.ncbi.nlm.nih.gov)

What to watch: Expect clinicians to keep refining where ropinirole fits in practice, especially as more real-world emergency data emerge comparing speed, first-dose success, protracted vomiting, and the need for rescue antiemetics. Separately, antiemetic options are also evolving: Dechra says its newly approved maropitant injectable, Emeprev, a bioequivalent to the leading antiemetic, is expected through major veterinary distributors in early 2026, with no refrigeration required and reduced injection pain in dogs due to benzyl alcohol in the formulation. (pubmed.ncbi.nlm.nih.gov)